Advertisement

Journal of Gastroenterology

, Volume 52, Issue 3, pp 366–375 | Cite as

The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients

  • Ayako Urabe
  • Michio Imamura
  • Masataka Tsuge
  • Hiromi Kan
  • Hatsue Fujino
  • Takayuki Fukuhara
  • Keiichi Masaki
  • Tomoki Kobayashi
  • Atsushi Ono
  • Takashi Nakahara
  • Tomokazu Kawaoka
  • Akira Hiramatsu
  • Yoshiiku Kawakami
  • Hiroshi Aikata
  • Clair Nelson Hayes
  • Noboru Maki
  • Hideaki Ohdan
  • Kazuaki ChayamaEmail author
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

Post-transplant hepatitis B virus (HBV) reinfection is one of the major problems facing patients who undergo HBV-related liver transplantation (LT). We analyzed the clinical impact of serum hepatitis B core-related antigen (HBcrAg) on HBV reinfection in post-LT patients with HBV-related liver diseases.

Methods

Serum hepatitis B surface antigen (HBsAg), HBV DNA, and HBcrAg were measured over time in 32 post-LT patients. Twenty-one out of 32 patients had HCC at LT. The effects of HBcrAg, hepatocellular carcinoma (HCC) recurrence, and HBs gene mutation on HBV reinfection and withdrawal from hepatitis B immune globulin (HBIG) were analyzed.

Results

Sixteen out of 32 patients (50 %) were positive for HBcrAg even though only six patients were thought to have experienced HBV reinfection based on reappearance of either HBV DNA or HBsAg during a median follow-up time of 75 months. Three of these six patients who became re-infected with HBV experienced HCC recurrence after LT. The HBV DNA reappearance rate was significantly higher in patients with HCC recurrence after LT (p < 0.001). Two HBV re-infected patients without HCC recurrence had HBs gene mutations G145R and G145A, respectively. Anti-HBs antibody development rate by HB vaccination was similar between HBcrAg-positive and negative patients (p = 0.325).

Conclusions

HBV reinfection is more common than is usually considered based on conventional measurement of HBsAg and HBV DNA. HCC recurrence and mutations in the HBV S gene were associated with HBV reinfection after LT.

Keywords

Liver transplantation HBV reinfection HBcrAg HBs gene mutations Hepatitis B immune globulin 

Abbreviations

ADV

Adefovir

ALT

Alanine aminotransferase

BCP

Basal core promoter

ccc

Covalently closed circular

CLEIA

Chemiluminescence enzyme immunoassay

ETV

Entecavir

HBcAg

Hepatitis B core antigen

HBcrAg

Hepatitis B core-related antigen

HBeAg

Hepatitis B e antigen

HBIG

Hepatitis B immune globulin

HCC

Hepatocellular carcinoma

HBsAg

Hepatitis B surface antigen

HBsAb

Anti-hepatitis B surface antibody

HBV

Hepatitis B virus

HCV

Hepatitis C virus

LAM

Lamivudine

LT

Liver transplantation

NA

Nucleos(t)ide analogue

PBMC

Peripheral blood mononuclear cells

PCR

Polymerase chain reaction

TMA

Transcription-mediated amplification assay

Notes

Acknowledgments

The authors thank Rie Akiyama for expert technical help and Akemi Sata and Emiko Nishio for technical assistance.

Compliance with ethical standards

Conflict of interest

Kazuaki Chayama received honoraria from MSD K.K., Bristol-Meyers Squibb, Gilead Sciences, and AbbVie; and research funding from Dainippon Sumitomo Pharma, TORAY, Eisai, Otsuka Pharma, Mitsubishi Tanabe Pharma, Daiichi Sankyo, and Bristol-Meyers Squibb. Michio Imamura received honoraria and research funding from Bristol-Meyers Squibb. Masataka Tsuge received research funding from Bristol-Meyers Squibb.

Funding

This research is partially supported by research funding from the Research Program on Hepatitis from the Japan Agency for Medical Research and Development, AMED (Grant Number: 15fk0210001h0002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Supplementary material

535_2016_1240_MOESM1_ESM.tiff (1.5 mb)
Supplementary Fig. 1. The clinical course of Case 3. The patient experienced HCC recurrence and HBsAg reappearance after LT. HBsAg reappearance was linked closely with HCC recurrence (TIFF 1521 kb)

References

  1. 1.
    Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology. 1991;13(4):619–26.PubMedPubMedCentralGoogle Scholar
  2. 2.
    O’Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992;14(1):104–11.CrossRefPubMedGoogle Scholar
  3. 3.
    Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation (2). N Engl J Med. 1989;321(16):1092–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329(25):1842–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet. 1996;348(9036):1212–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998;28(2):585–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002;35(6):1528–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology. 2003;38(1):86–95.CrossRefPubMedGoogle Scholar
  9. 9.
    Saab S, Yeganeh M, Nguyen K, et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transplant. 2009;15(11):1525–34.CrossRefGoogle Scholar
  10. 10.
    Faria LC, Gigou M, Roque-Afonso AM, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology. 2008;134(7):1890–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology. 2000;31(2):496–501.CrossRefPubMedGoogle Scholar
  12. 12.
    Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology. 2002;35(1):176–81.CrossRefPubMedGoogle Scholar
  13. 13.
    Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol. 2001;34(6):888–94.CrossRefPubMedGoogle Scholar
  14. 14.
    Dodson SF, de Vera ME, Bonham CA, et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl. 2000;6(4):434–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005;128(7):1890–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Suzuki F, Miyakoshi H, Kobayashi M, et al. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol. 2009;81(1):27–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol. 2002;40(2):439–45.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Yasunaka T, Takaki A, Yagi T, et al. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int. 2011;5(4):918–26.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Matsuzaki T, Tatsuki I, Otani M, et al. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. Gastroenterol Hepatol. 2013;28(7):1217–22.CrossRefGoogle Scholar
  20. 20.
    Tsuge M, Hiraga N, Takaishi H, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology. 2005;42(5):1046–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Wong DK, Yuen MF, Poon RT, et al. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol. 2006;45(4):553–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Tanaka E, Matsumoto A, Suzuki F, et al. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. Liver Int. 2006;26(1):90–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Hosaka T, Suzuki F, Kobayashi M, et al. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int. 2010;30(10):1461–70.CrossRefPubMedGoogle Scholar
  24. 24.
    Honda M, Shirasaki T, Terashima T, et al. HBcrAg during nucleos(t)ide analog therapy are related to intra-hepatic HBV replication and development of hepatocellular carcinoma. J Infect Dis. 2016;213(7):1096–106.CrossRefPubMedGoogle Scholar
  25. 25.
    Wu TJ, Chan KM, Chou HS, et al. Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome. Ann Surg Oncol. 2013;20(11):3582–90.CrossRefPubMedGoogle Scholar
  26. 26.
    Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology. 2000;32(6):1189–95.CrossRefPubMedGoogle Scholar
  27. 27.
    Mohanty SR, Cotler SJ. Management of hepatitis B in liver transplant patients. J Clin Gastroenterol. 2005;39(1):58–63.PubMedGoogle Scholar
  28. 28.
    Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology. 1998;27(1):254–63.CrossRefPubMedGoogle Scholar
  29. 29.
    Gane EJ, Patterson S, Strasser SI, et al. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl. 2013;19(3):268–74.CrossRefPubMedGoogle Scholar
  30. 30.
    Teperman LW, Poordad F, Bzowej N, et al. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl. 2013;19(6):594–601.CrossRefPubMedGoogle Scholar
  31. 31.
    Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011;141(4):1212–9.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2016

Authors and Affiliations

  • Ayako Urabe
    • 1
  • Michio Imamura
    • 1
  • Masataka Tsuge
    • 1
  • Hiromi Kan
    • 1
  • Hatsue Fujino
    • 1
  • Takayuki Fukuhara
    • 1
  • Keiichi Masaki
    • 1
  • Tomoki Kobayashi
    • 1
  • Atsushi Ono
    • 1
  • Takashi Nakahara
    • 1
  • Tomokazu Kawaoka
    • 1
  • Akira Hiramatsu
    • 1
  • Yoshiiku Kawakami
    • 1
  • Hiroshi Aikata
    • 1
  • Clair Nelson Hayes
    • 1
  • Noboru Maki
    • 2
  • Hideaki Ohdan
    • 3
  • Kazuaki Chayama
    • 1
    Email author
  1. 1.Department of Gastroenterology and Metabolism, Applied Life ScienceInstitute of Biomedical and Health Science, Hiroshima University, Hiroshima UniversityHiroshimaJapan
  2. 2.Advanced Life Science Institute, Inc.WakoJapan
  3. 3.Division of Frontier Medical Science, Department of Surgery, Programs for Biomedical ResearchGraduate School of Biomedical Science, Hiroshima UniversityHiroshimaJapan

Personalised recommendations